‘Cutting the cable’ between CD8+ T and T regulatory cells enhances checkpoint immunotherapy

Checkpoint immunotherapy utilizing PD-1 blockade has become the standard of care for metastatic melanoma. While this treatment is effective in 40 percent of patients, the other 60 percent develop resistance, leading to tumor regrowth. 

Read More